Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia

Clin Infect Dis. 2020 Sep 12;71(6):1413-1418. doi: 10.1093/cid/ciz995.

Abstract

Cefazolin and ertapenem combination therapy was used successfully to salvage 11 cases (6 endocarditis) of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (≤24 hours) in 8 cases. While in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in a rat model of MSSA endocarditis. The combination of cefazolin and ertapenem provides potent in vivo activity against MSSA beyond what is predicted in vitro and warrants further clinical study in the treatment of refractory MSSA bacteremia and endocarditis.

Keywords: Staphylococcus aureus; bacteremia; cefazolin; endocarditis; ertapenem.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / drug therapy
  • Cefazolin / therapeutic use
  • Ertapenem
  • Methicillin / pharmacology
  • Rats
  • Salvage Therapy
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus

Substances

  • Anti-Bacterial Agents
  • Ertapenem
  • Cefazolin
  • Methicillin